MANISTIQUE, Mich. (WLUC) – A U.P. hospital has launched a new FDA-approved targeted therapy for patients with advanced metastatic prostate cancer.
Schoolcraft Memorial Hospital is collaborating with Green Bay Oncology to launch a new Nuclear Medicine service line offering Pluvicto (lutetium Lu-177 vipivotide tetraxetan), according to a Monday afternoon press release from the hospital.
The release says this addition makes Schoolcraft Memorial Hospital the only provider in the U.P. offering this specialized treatment…